Edwina Gildea

Dr. Edwina Gildea


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 May 2024 in Frontiers in Veterinary Science
Verified
Journal Article
Open access
EGEdwina Gildea
Edwina Gildea
ESEmma Scales-Theobald
Emma Scales-Theobald
JTJill Thompson
Jill Thompson
ACAlasdair Cook
Alasdair Cook
KFKatie Forde
Katie Forde
CPCharlotte Panter
Charlotte Panter
Introduction: Canine osteoarthritis (OA) causes pain and mobility impairment. This can reduce dog quality of life (QoL), owner QoL and owners’ satisfaction with, and adherence to, treatments. No existing canine OA-specific instrument assesses all three impacts. This study aimed to develop and psychometrically evaluate an owner-completed canine OA-specific measure of dog QoL, owner QoL and owner treatment satisfaction; the “Canine OA Quality of Life and Treatment Satisfaction Questionnaire” (CaOA-QoL-TS).Methods: The CaOA-QoL-TS was developed using a conceptual model derived from a meta-synthesis of published literature followed by cognitive interviews with ten owners of dogs with OA, to evaluate content validity.Results: Based on interview findings, ten items were reworded, four removed, and two added; resulting in 26 items that all owners understood and considered relevant. The recall period and response options were well understood and appropriate to almost all owners. To evaluate its psychometric properties, the CaOA-QoL-TS (draft 26-item version) was administered, across six timepoints in a phase 4 field study, to owners of OA treated dogs, recruited from veterinary practices (N = 93). Inter-item correlations suggested items clustered into three distinct domains: Dog QoL, Owner QoL and Treatment Satisfaction, as hypothesized. Confirmatory factor analysis supported deletion of two items and calculation of the three domain scores, with acceptable model fit. The resulting 24-item CaOA-QoL-TS instrument demonstrated strong internal consistency and good to excellent test–retest reliability. Convergent validity was supported by moderate to strong correlations with concurrent measures. Known groups validity was supported by statistically significant differences between groups categorized by owner global impression of QoL. Ability to detect change was demonstrated through statistically significant improvements over time in Owner and Dog QoL, with larger within-group effect sizes reported for the mean of ‘improved’ dogs compared to the mean of ‘stable’ dogs. Only a small sample of dogs worsened throughout the study. Anchor-based analyses supported-0.9 and-1.0-point within-group responder definitions for dog and owner QoL domains, respectively.Discussion: Findings support the content validity of the CaOA-QoL-TS in canine OA. The 24-item CaOA-QoL-TS is a reliable and valid instrument to measure owner and canine QoL and TS and is sensitive to improvements following OA treatment.

31 July 2024 in Animals
Verified
Journal Article
Open access
PDF file
EGEdwina Gildea
Edwina Gildea
RWRobin Wyn
Robin Wyn
KWKatherine Walker
Katherine Walker
FAFrancis Adriaens
Francis Adriaens
DLDuncan X Lascelles
Duncan X Lascelles
Bedinvetmab (Librela®) represents a new class of canine osteoarthritis pain therapy. The aim of this study was to understand patient selection, usage behaviours, and satisfaction amongst veterinarians using bedinvetmab. Overall, 1932 patient record forms (PRF) were collected from 375 veterinarians across five countries in Europe. Veterinarians were asked to provide 5–7 PRF representing an average patient prescribed bedinvetmab. Veterinarian satisfaction with bedinvetmab usage averaged 8.0 out of 10.0 across all countries. Dissatisfaction as a reason for discontinuation was less than 1% for veterinarians. Veterinarians prescribed bedinvetmab broadly, across patient severity stages, weights, and ages. Adherence to monthly dosing per the product label was over 99%, and compliance with bedinvetmab treatment regimens was 85%. Following initiation of bedinvetmab, the proportion of patients requiring multiple pharmacological therapies for osteoarthritis pain fell from 47% to 31% (p < 0.05). After initiation of bedinvetmab, the mean total number of pharmacological therapies per patient across the population was 1.3, a reduction from 1.9 pre-treatment (p < 0.05). This investigation provides evidence on the benefit of bedinvetmab use post-launch in a broad population of dogs across the five most populous countries in western Europe. Compliance and satisfaction appear high and the use of other analgesic therapies to treat osteoarthritis pain is reduced in most cases following administration of bedinvetmab.

8 August 2024 in Animals
Verified
Journal Article
Open access
PDF file
AWAndrea Wright
Andrea Wright
EGEdwina Gildea
Edwina Gildea
LLLouise Longstaff
Louise Longstaff
DRDanielle Riley
Danielle Riley
NNNirav Nagda
Nirav Nagda
RWRobin Wyn
Robin Wyn
This research aimed to explore UK cat owners’ preferences for treatments for feline osteoarthritis (OA) by exploring preferences around quality of life (QoL) improvements, safety considerations, and costs associated with hypothetical innovative pain therapies. Aspects identified in an existing conceptual framework were extracted for inclusion in exploratory interviews with cat owners (n = 3) to identify key domains that contribute to the QoL of cats. QoL descriptions for cats with OA and hypothetical product attributes were developed and validated through interviews with veterinarians (n = 3). An online survey was subsequently shared with 255 pet owners in the UK. Pet owners were presented with QoL descriptions and hypothetical product attributes to gather their preferences for QoL improvements and their willingness to pay (WTP) for (unbranded) pain therapies at various price points. Pet owners were motivated to improve their cats’ QoL, which translated into WTP for therapies; specifically, pet owners valued QoL improvements in mobility, pain expression, and well-being. When presented with a product profile of the hypothetical novel monoclonal antibody (mAb) and cost, 50% of cat owners were willing to pay more for a mAb that is expected to have improved efficacy and safety when compared to a hypothetical standard of care (SoC). Significantly more pet owners preferred the mAb than the SoC when price was not presented (p < 0.01), with product efficacy and safety driving pet owners’ decision-making. The majority of pet owners did not agree that taking their cats to the veterinarian once a month for their treatment would be burdensome. Cat owners in the UK are motivated to improve their cats’ QoL, which translates into WTP for the efficacious treatment of pain associated with osteoarthritis. Veterinarians should offer cat owners the pain treatment they feel is best suited for improving the cat’s QoL and to ensure subsequent owner-pet bond is preserved.

7 August 2026 in Frontiers in Veterinary Science
Verified
Journal Article
Open access
PDF file
EGEdwina Gildea
Edwina Gildea
JTJill Thompson
Jill Thompson
ACAlasdair Cook
Alasdair Cook
GSGeorge Skingley
George Skingley
AFAmy Findley
Amy Findley
ALAoife Lydon
Aoife Lydon
Introduction: Osteoarthritis (OA) in cats causes pain and mobility impairment, negatively impacting quality of life (QoL) of cats and their owners. Owner-perceived treatment satisfaction can influence treatment adherence and subsequent health outcomes for the cat. Currently, no OA-specific instrument for cats assesses all three concepts. This study aimed to address this gap by developing and psychometrically evaluating an owner-completed feline OA-specific measure—the “Feline OA Quality of Life and Treatment Satisfaction Assessment” (FeOA-QoL-TS-A)—to measure cat QoL, owner QoL, and owner treatment satisfaction. Methods: A mixed-methods approach was used. The draft FeOA-QoL-TS-A was developed using a conceptual model derived from an earlier meta-synthesis of published literature and supplementary review. Qualitative interviews were then conducted with eight owners of cats with OA to evaluate the content validity of the draft FeOA-QoL-TS-A. The revised FeOA-QoL-TS-A was then administered to owners of OA-treated cats ( n = 139) at six timepoints during a phase 4 field study to evaluate the psychometric properties of the resulting item-scale structure. Results: Interview findings informed revisions to the draft 25-item FeOA-QoL-TS-A, which was well understood by owners. Item-level analysis and confirmatory factor analysis supported the removal of five items and confirmed the structure of three distinct domains: Cat QoL, Owner QoL, and Treatment Satisfaction. The final 20-item FeOA-QoL-TS-A demonstrated good internal consistency and test–retest reliability. Convergent validity was supported by strong correlations with concurrent measures. Known groups comparisons provided strong evidence that the instrument can differentiate between groups with varying QoL levels. Ability to detect improvement in Cat and Owner QoL domains was demonstrated through statistically significant improvements over time, with larger effect sizes reported for the ‘improved’ group compared with the ‘stable’ group. Anchor-based analyses supported −1.0 and −0.9-point responder definitions for Cat and Owner QoL domains, respectively. Conclusion: The final 20-item FeOA-QoL-TS-A is a valid, reliable, and responsive instrument for assessing OA-specific cat QoL, owner QoL, and treatment satisfaction. Its flexible domain structure supports application in veterinary practice, stakeholder communications, and clinical research endpoints. The FeOA-QoL-TS-A addresses a critical measurement gap by providing a comprehensive and practical solution to evaluate the multifaceted impacts of feline OA.

11 February 2025 in Animals
Verified
Journal Article
Open access
PDF file
AWAndrea Wright
Andrea Wright
EGEdwina Gildea
Edwina Gildea
MGMichelle Greaves
Michelle Greaves
LLLouise Longstaff
Louise Longstaff
RWRobin Wyn
Robin Wyn
OHOliver Handley
Oliver Handley
A web-based quantitative survey tested pet owners’ preferences and willingness-to-pay for canine anti-pruritus therapies, and for improvements in pruritus-related quality of life. This survey was designed using findings from recent research into quality of life in pruritus, interviews with pet owners and veterinarians, and clinical and cost data. The survey was completed by 251 dog owners in the United Kingdom. A total of 46–47% were willing to pay to improve individual concepts of pruritus-related quality of life, including comfort, scratching behavior, and appearance. Instituting treatment to manage pruritus and the investigation of pruritus causes were considered important actions; safety and effectiveness were the most important attributes of therapy. Comparing the administration, effectiveness, safety, and costs of (unbranded) therapy profiles, on average, 63% preferred hypothetical tablet or injectable therapies (with higher cost and improved safety) over corticosteroid treatment for acute pruritus (p < 0.05). Over 50% of respondents preferred the hypothetical therapies in all tested subgroups, and results were similar for chronic pruritus. This research highlighted that many pet owners are willing to pay to improve their pet’s quality of life, and to receive comparably effective, yet safer therapies for the management of acute canine pruritus, regardless of insurance status. Veterinarians should consider discussing and offering newly available therapies for acute and chronic pruritus with pet owners where medically appropriate.